Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript

PresentationOperator Good morning, and welcome to Ocugen's webcast to discuss data from the first half of patients completing 1 year since treatment in the OCU410 Phase II ArMaDa clinical trial for geographic atrophy. Please note that this call is being recorded at this time. [Operator Instructions] Joining on today's webcast are Dr. Shankar Musunuri, Chairman, CEO and Co-Founder; Dr. Huma Qamar, Chief Medical Officer; and Dr. Arun Upadhyay, Chief Scientific Officer, along with distinguished clinical trial ...